Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Insmed CEO Geoffrey Allan Testifies at Congressional Hearing
April 11th, 2007
Insmed, Inc. (NASDAQ:INSM) President and Chief Executive Officer, Geoffrey Allan, Ph. D., testified today at a congressional hearing, "Safe and Affordable Biotech Drugs - The Need for a Generic Pathway." Dr. Allan was a witness before the House of Representatives Oversight and Government Reform Committee Majority Staff hearing. He, along with other industry and regulatory experts, shared his views on the role of biotech companies in the debate on the need for a generic pathway for biologics. Currently, the FDA lacks clear authority to approve a generic form of a biologic medication. Biologics comprise one of the fastest growing and most expensive...
Source: Medical Patent Law Weekly (2007-04-11)
|
